Cancer proteomics is a field of scientific research which analysis protein changes in cancer. Oncological drug development is facilitated by understanding which proteins are differentially expressed in tumors and healthy tissue. Also, protein changes occurring throughout disease progression can be used to assess prognosis or aid in treatment planning.
DATE: May 26, 2016TIME: 8am pacific time, 11am eastern timeJoin us live and learn about a breakthrough in TCR sequencing using single-cell analysis.T cells recognize spe...
DATE: May 17, 2016
TIME: 7am Pacific time, 10am Eastern time, 4pm Swedish time
Data generation is becoming easier and easier and many organizations have matured in their data storage and ...
Self-assembling protein microarrays arrays can be used to study protein-protein interactions, protein-drug interactions, search for enzyme substrates, and as tools to search for disease bioma...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Date: Dec 1, 2015 7:00am Pacific, 9:00am Central, 10:00am Eastern, 4pm European Time
Data generation is becoming easier and easier but within the fields of bioinformatics and data analysis...
DATE: November 4th, 2015
TIME: 11:00am Pacific time, 2:00pm Eastern time
AMPK, a highly conserved sensor of cellular energy status, is found in all eukaryotic cells and maintains met...
During the development of oral cancer (OC), cancer-associated fibroblasts (CAFs) create a supporting niche by maintaining a bidirectional crosstalk with cancer cells, mediated by classically ...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
Biological datasets have become increasing large and complex. Knowledge databases and publicly available datasets are available for use in experimental planning and running results comparison...
Cancers exhibit abnormal molecular signatures associated with disease initiation and progression. Molecular signatures could improve cancer screening, detection, drug development and selectio...
Extracellular vesicles (EVs) include the exosomes (30-100 nm) that are produced through the endocytic pathway via the multivesicular bodies and the ectosomes (100-1000 nm) that are released t...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
Although robust and clinically meaningful biomarkers are key to achieving the current vision for precision (molecularly based), cancer medicine (patient stratification, early diagnosis, drug...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
The human genome encodes ~21,500 proteins that are subject to reversible phosphorylation at nearly 1 million phosphosites by about 538 protein kinases and 156 protein phosphatases. Amongst ot...
Pharmcogenomics (PGx) is the 2nd potential clinical application of genomic medicine, preceded by genomic application for cancer. In the recently published, 2012 Institute of Medicine report o...
The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spit...
Cancer cells have historically been classified by microscopic analysis of blood smears and tissue sections. Current technologies use molecular techniques to categorize and classify tumor cell...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
DATE: May 26, 2016TIME: 8am pacific time, 11am eastern timeJoin us live and learn about a breakthrough in TCR sequencing using single-cell analysis.T cells recognize spe...
DATE: May 17, 2016
TIME: 7am Pacific time, 10am Eastern time, 4pm Swedish time
Data generation is becoming easier and easier and many organizations have matured in their data storage and ...
Self-assembling protein microarrays arrays can be used to study protein-protein interactions, protein-drug interactions, search for enzyme substrates, and as tools to search for disease bioma...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Date: Dec 1, 2015 7:00am Pacific, 9:00am Central, 10:00am Eastern, 4pm European Time
Data generation is becoming easier and easier but within the fields of bioinformatics and data analysis...
DATE: November 4th, 2015
TIME: 11:00am Pacific time, 2:00pm Eastern time
AMPK, a highly conserved sensor of cellular energy status, is found in all eukaryotic cells and maintains met...
During the development of oral cancer (OC), cancer-associated fibroblasts (CAFs) create a supporting niche by maintaining a bidirectional crosstalk with cancer cells, mediated by classically ...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
Biological datasets have become increasing large and complex. Knowledge databases and publicly available datasets are available for use in experimental planning and running results comparison...
Cancers exhibit abnormal molecular signatures associated with disease initiation and progression. Molecular signatures could improve cancer screening, detection, drug development and selectio...
Extracellular vesicles (EVs) include the exosomes (30-100 nm) that are produced through the endocytic pathway via the multivesicular bodies and the ectosomes (100-1000 nm) that are released t...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
Although robust and clinically meaningful biomarkers are key to achieving the current vision for precision (molecularly based), cancer medicine (patient stratification, early diagnosis, drug...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
The human genome encodes ~21,500 proteins that are subject to reversible phosphorylation at nearly 1 million phosphosites by about 538 protein kinases and 156 protein phosphatases. Amongst ot...
Pharmcogenomics (PGx) is the 2nd potential clinical application of genomic medicine, preceded by genomic application for cancer. In the recently published, 2012 Institute of Medicine report o...
The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spit...
Cancer cells have historically been classified by microscopic analysis of blood smears and tissue sections. Current technologies use molecular techniques to categorize and classify tumor cell...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
